Shares of Proteon Therapeutics Inc (NASDAQ:PRTO) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $3.43.
PRTO has been the subject of a number of recent analyst reports. Robert W. Baird reissued a “hold” rating and set a $2.00 target price on shares of Proteon Therapeutics in a research note on Friday, November 10th. HC Wainwright reissued a “hold” rating and set a $2.30 target price on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Finally, Zacks Investment Research lowered shares of Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th.
In other Proteon Therapeutics news, Director James E. Flynn acquired 110,557 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was bought at an average cost of $1.75 per share, with a total value of $193,474.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders purchased 122,852 shares of company stock valued at $216,533. 36.30% of the stock is owned by insiders.
Shares of Proteon Therapeutics (PRTO) traded up $0.20 on Friday, hitting $2.40. 57,667 shares of the stock were exchanged, compared to its average volume of 93,712. The stock has a market capitalization of $40.52, a price-to-earnings ratio of -1.04 and a beta of 1.78. Proteon Therapeutics has a 1 year low of $1.10 and a 1 year high of $2.85.
Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.68). sell-side analysts predict that Proteon Therapeutics will post -1.88 earnings per share for the current fiscal year.
WARNING: “Proteon Therapeutics Inc (PRTO) Receives Consensus Recommendation of “Hold” from Brokerages” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2018/02/07/proteon-therapeutics-inc-prto-receives-consensus-recommendation-of-hold-from-brokerages.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.